Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Net Income (2022 - 2025)

Entrada Therapeutics has reported Net Income over the past 4 years, most recently at -$39.1 million for Q4 2025.

  • Quarterly results put Net Income at -$39.1 million for Q4 2025, down 3737.55% from a year ago — trailing twelve months through Dec 2025 was -$143.8 million (down 319.16% YoY), and the annual figure for FY2025 was -$143.7 million, down 319.09%.
  • Net Income for Q4 2025 was -$39.1 million at Entrada Therapeutics, up from -$44.2 million in the prior quarter.
  • Over the last five years, Net Income for TRDA hit a ceiling of $55.0 million in Q2 2024 and a floor of -$44.2 million in Q3 2025.
  • Median Net Income over the past 4 years was -$19.5 million (2022), compared with a mean of -$11.2 million.
  • Biggest five-year swings in Net Income: soared 452.05% in 2024 and later crashed 3737.55% in 2025.
  • Entrada Therapeutics' Net Income stood at -$24.6 million in 2022, then skyrocketed by 61.25% to -$9.5 million in 2023, then soared by 111.27% to $1.1 million in 2024, then crashed by 3737.55% to -$39.1 million in 2025.
  • The last three reported values for Net Income were -$39.1 million (Q4 2025), -$44.2 million (Q3 2025), and -$43.1 million (Q2 2025) per Business Quant data.